Inmuno-quimioterapia en los linfomas indolestes B. Resultados de dos estudios prospectivos multicéntricos: LNH-PRO y LNH-PRO-05. Análisis a largo plazo del esquema CVP-IFNa 2b (Ensayo LNH-PRO). Resultados terapéuticos con doble inmunoterapia (R-CVP-IFN) en el Linfoma folicular con FLIPI intermedio-alto y alto riesgo (Ensayo LNH-PRO-05)

Tesis doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Medicina. Fecha de lectura: 22-09-2017Esta tesis tiene embargado el acceso al texto completo hasta el 22-03-201

First line treatment with rituximab-Hyper-CVAD alternating with rituximab-Methotrexate-Cytarabine and followed by consolidation with 90Y-Ibritumomab-Tiuxetan in patients with mantle cell lymphoma. Results of a phase 2 pilot multicenter trial from the GELT

D. First line treatment with rituximab-Hyper-CVAD alternating with rituximab-Methotrexate-Cytarabine and followed by consolidation with 90Y-Ibritumomab-Tiuxetan in patients with mantle cell lymphoma. Results of a phase 2 pilot multicenter trial from th

Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT. Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture. Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.SCOPUS: re.jinfo:eu-repo/semantics/publishe

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

During 2009, a new strain of A/H1N1 influenza appeared and became pandemic. A prospective study was performed to collect data regarding risk factors and outcome of A/H1N1 in hematopoietic stem cell transplant recipients. Only verified pandemic A/H1N1 influenza strains were included: 286 patients were reported, 222 allogeneic and 64 autologous recipients. The median age was 38.3 years and the median time from transplant was 19.4 months. Oseltamivir was administered to 267 patients and 15 patients received zanamivir. One hundred and twenty-five patients (43.7%) were hospitalized. Ninety-three patients (32.5%) developed lower respiratory tract disease. In multivariate analysis, risk factors were age (OR 1.025; 1.01–1.04; P=0.002) and lymphopenia (OR 2.49; 1.33–4.67; P<0.001). Thirty-three patients (11.5%) required mechanical ventilation. Eighteen patients (6.3%) died from A/H1N1 infection or its complications. Neutropenia (P=0.03) and patient age (P=0.04) were significant risk factors for death. The 2009 A/H1N1 influenza pandemic caused severe complications in stem cell transplant recipients